Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

bination with docetaxel retreatment have indicated that OGX-011 may help restore tumor sensitivity to docetaxel and may improve overall survival for second-line therapy."

The planned initiation of this Phase 3 trial is supported by encouraging preliminary Phase 2 data that were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). These preliminary data are derived from a Phase 2 study evaluating 42 patients with HRPC who had received first-line docetaxel therapy and required second-line chemotherapy: 22 patients were treated with mitoxantrone plus OGX-011 and 20 patients with docetaxel retreatment plus OGX-011. While follow up on surviving patients is still ongoing, the following preliminary findings were reported:

- Survival continued to be better than expected based on previously

published reports: With a median follow-up of 17.2 months following the

start of second-line chemotherapy, median survival has been estimated

at 11.4 months in the mitoxantrone plus OGX-011 group and 14.7 months

in the docetaxel retreatment plus OGX-011 group. These data compare

favorably with published results reporting median survivals at

approximately 10 months for HRPC patients receiving second-line

chemotherapy without OGX-011.

- In addition, average serum clusterin levels during treatment were

predictive of survival, with low-average levels predicting median

survival time of 14.7 months compared to high-average levels predicting

median survival time of 5.5 months. These data suggest that a reduction

in clusterin levels may improve survival.

About OGX-011

OGX-011 is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer indications and in response to many cancer treatments. Increased clusterin production is observed in many human cancers, including prostate, non-small c
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... COSTA MESA, Calif. , July 24, 2014 /PRNewswire/ ... incredibly close to home. Rehealth Regenerative Therapies , ... offering athletes and other physically active people a new ... . Regardless of age, countless patients suffer ... amateur sport activities, such as muscle tears, torn rotator ...
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... Jerusalem, July 21, 2010 -- Scientists from the Hebrew ... is possible to greatly expand the memory capacity of ... on silica nanoparticles combined with protein molecules obtained from ... say, they have developed an alternative avenue to miniaturize ...
... 21 The Lucian Leape Institute at the National ... special evening program at its Third Annual Forum & ... Blumenthal, M.D., M.P.P., will deliver a keynote address at the ... patient safety lever and the focus placed on its development ...
... DALLAS , July ... report "Bioinformatics Market - Advanced Technologies, Global,Forecast and Winning ... bioinformatics market is,expected to reach a $8.3 billion ... from,2009-2014. While knowledge management formed the largest submarket is ...
Cached Biology Technology:Protein from poplar trees can be used to greatly increase computer capacity 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 3David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 4MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 2MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 3MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 4
(Date:7/24/2014)... that successfully treated lupus in mice, a biomedical engineer at ... expand his research to a new version of the drug ... diseases., Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed ... in Arthritis Research & Therapy outlining the use of a ... the number of cases of lupus-related kidney disease., He now ...
(Date:7/24/2014)... , July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... announces its next generation smart wallet, Wocket™, was recently the topic ... Finley interviewed Gino Pereira , CEO of ... minutes. Mr. Gino Pereira ... full of credit cards and walks host Anita ...
(Date:7/23/2014)... been abused or neglected early in life are ... health problems. In a new study, scientists have ... activated, which has implications for children,s long-term development. ... individual characteristics and genetics interacted with that child,s ... problems emerge. In the new study, researchers were ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3
... reason for the weight-conscious to drink fat free milk,at breakfast ... of,the American Journal of Clinical Nutrition . Researchers in ... increase,satiety, or a feeling of fullness, and led to decreased ... drink. The milk drinkers ate,about 50 fewer calories (or nearly ...
... Notch signaling helps determine the fate of a number ... humans. In an article that appears in the current issue ... of Medicine report that a new finding about the Notch ... fly could explain the mystery behind an immunological disorder called ...
... Dissolved organic carbon (DOC) losses from tile drains ... This is particularly important in the eastern corn belt ... management practices, such as manure application, can play a ... organic carbon is applied to or injected into the ...
Cached Biology News:Drinking milk in the morning may help stave off lunchtime hunger 2Fate in fly sensory organ precursor cells could explain human immune disorder 2Fate in fly sensory organ precursor cells could explain human immune disorder 3Study of agricultural watersheds and carbon losses 2
... Anti-Natural Killer Cell Receptor-P1, clone ... Hybridoma produced by ... BALB/c mice immunized (BALB/c X ... cells and mouse myeloma cellline. ...
... monoclonal [YPF19] to Yersinia pestis ... Yersinia pestis . Immunogen: ... Yersinia pestis vaccine strain EV76. ... recognises Y.pestis F1 capsular antigen. There ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: